Tag: HydraSpace
Acquisition of Synaffix Strengthens Lonza’s Bioconjugates Offering
In a statement earlier today, Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, confirmed that it has acquired Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugates (ADCs).
South Korean Chong Kun Dang Pharm Licenses Synaffix Platform Technology
South Korean's Chong Kun Dang Pharm (CKD) has entered a licensing agreement with Netherlands-based Synaffix for the development of novel antibody-drug conjugates (ADCs) with best-in-class therapeutic index.
Amgen and Synafix Sign US $2 Billion License Agreement
Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), confirmed that it had signed...
Emergence Therapeutics Becomes the 10th Company to License Synaffix’ ADC Platform...
In a statement earlier today, Dutch-biotech Synaffix and German Emergence Therapeutics announced that the Companies have entered into a licensing agreement of up to...
Kyowa Kirin Expands License Agreement with Synaffix
Japanese pharmaceutical and biotechnology company Kyowa Kirin has expanded its license agreement with The Netherlands based Synaffix with one new antibody-drug conjugates (ADC) target added to...
Novel Linker-Drug Technology Enables Antibody-Drug Conjugates with an Expanded Therapeutic Window
Preclinical data from a novel, proprietary ADC technology platform being developed by ProfoundBio was being presented at the 2021 Molecular Targets and Cancer Therapeutics...
Synaffix and ADC Therapeutics Expand Collaboration
The Netherlands-based biotechnology company Synaffix and Swiss-based ADC Therapeutics have expanded the existing collaboration between the companies to explore additional applications of Synaffix’ site-specific...
Shanghai Miracogen and Synaffix Confirm Expansion of License Agreement
Netherlands-based biotech company Synaffix earlier today confirmed the expansion of a license agreement with Shanghai Miracogen, a Chinese biotechnology company with a clinical-stage pipeline...
Abzena Confirms Successful Technical Transfer of Synaffix’s GlycoConnect™ and HydraSpace™ Technologies
Earlier today Abzena confirmed that it had successfully completed a technology transfer and scalability evaluation using the Synaffix's technologies of GlycoConnect™, site-specific antibody-drug conjugation...
ADC Therapeutics Expands Agreement with Synaffix
The Netherlands-based biotechnology company Synaffix, which develops clinical-stage technologies for the development of best-in-class antibody-drug conjugates or ADCs, confirmed that ADC Therapeutics has triggered...
